FrancophonIA/ELRC3.0 huggingface dataset:
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each syringe contains 0.7 mL of solution for injection.
Estonian: Abseamed 7000 RÜ/0,7 ml süstelahus süstlis Üks süstel sisaldab 0,7 ml lahust.
English: INFORMATION IN BRAILLE Abseamed 20,000 IU/0.5 mL
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 20 000 RÜ/0,5 ml
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/009
Estonian: Abseamed 5000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/009
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 9,000 IU/0.9 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 9000 RÜ/0,9 ml süstevedelik Alfaepoetiin i.v./s.c.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 30,000 IU/0.75 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 30 000 RÜ/0,75 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe EU/1/07/412/019
Estonian: Abseamed 9000 RÜ/0,9 ml süstelahus süstlis EU/1/07/412/019
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe EU/1/07/412/023
Estonian: Abseamed 30 000 RÜ/0,75 ml süstelahus süstlis EU/1/07/412/023
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe EU/1/07/412/011
Estonian: Abseamed 6000 RÜ/0,6 ml süstelahus süstlis EU/1/07/412/011
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Each syringe contains 0.3 mL of solution for injection.
Estonian: Abseamed 3000 RÜ/0,3 ml süstelahus süstlis Üks süstel sisaldab 0,3 ml lahust.
English: INFORMATION IN BRAILLE Abseamed 1,000 IU/0.5 mL
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 1000 RÜ/0,5 ml
English: INFORMATION IN BRAILLE Abseamed 3,000 IU/0.3 mL
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 3000 RÜ/0,3 ml
English: INFORMATION IN BRAILLE Abseamed 10,000 IU/1 mL
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 10 000 RÜ/1 ml
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Estonian: Abseamed 40 000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Estonian: Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/025
Estonian: Abseamed 40 000 RÜ/1 ml süstelahus süstlis EU/1/07/412/025
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 6,000 IU/0.6 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 6000 RÜ/0,6 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe EU/1/07/412/007
Estonian: Abseamed 4000 RÜ/0,4 ml süstelahus süstlis EU/1/07/412/007
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 8,000 IU/0.8 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 8000 RÜ/0,8 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 8000 RÜ/0,8 ml süstelahus süstlis Alfaepoetiin
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 4,000 IU/0.4 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 4000 RÜ/0,4 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/021
Estonian: Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/021
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Estonian: Abseamed 5000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe EU/1/07/412/017
Estonian: Abseamed 7000 RÜ/0,7 ml süstelahus süstlis EU/1/07/412/017
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe EU/1/07/412/005
Estonian: Abseamed 3000 RÜ/0,3 ml süstelahus süstlis EU/1/07/412/005
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Estonian: Abseamed 10 000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
English: INFORMATION IN BRAILLE Abseamed 2,000 IU/1 mL
Estonian: TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 2000 RÜ/1 ml
English: Do not shake Abseamed syringes.
Estonian: Abseamedi süstleid ei tohi loksutada.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 5,000 IU/0.5 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 5000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 40 000 RÜ/1 ml süstelahus süstlis Alfaepoetiin
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Estonian: Abseamed 1000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/015
Estonian: Abseamed 10 000 RÜ/1 ml süstelahus süstlis EU/1/07/412/015
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 3,000 IU/0.3 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 3000 RÜ/0,3 ml süstevedelik Alfaepoetiin i.v./s.c.
English: What is in this leaflet What Abseamed is and what it is used for What you need to know before you use Abseamed How to use Abseamed Possible side effects How to store Abseamed Contents of the pack and other information What Abseamed is and what it is used for Abseamed contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen).
Estonian: Mis ravim on Abseamed ja milleks seda kasutatakse Mida on vaja teada enne Abseamedi kasutamist Kuidas Abseamedi kasutada Võimalikud kõrvaltoimed
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/003
Estonian: Abseamed 2000 RÜ/1 ml süstelahus süstlis EU/1/07/412/003
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 1,000 IU/0.5 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 1000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 6000 RÜ/0,6 ml süstelahus süstlis
English: Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 9000 RÜ/0,9 ml süstelahus süstlis
English: Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa
Estonian: Abseamed 1000 RÜ/0,5 ml süstelahus süstlis Alfaepoetiin
English: Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 4000 RÜ/0,4 ml süstelahus süstlis
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Estonian: Abseamed 2000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
English: Abseamed should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)).
Estonian: Abseamedi tuleb manustada sümptomaatilise aneemiaga (nt hematoglobiinisisaldus ≤ 10 g/dl
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 40,000 IU/1 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 40 000 RÜ/1 ml süstevedelik Alfaepoetiin i.v./s.c.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 20,000 IU/0.5 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 20 000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
English: NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 10,000 IU/1 mL injection
Estonian: RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 10 000 RÜ/1 ml süstevedelik Alfaepoetiin i.v./s.c.
English: Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 3000 RÜ/0,3 ml süstelahus süstlis
English: Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/001
Estonian: Abseamed 1000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/001
English: Talk to your doctor, pharmacist or nurse before using Abseamed.
Estonian: Enne Abseamedi kasutamist pidage nõu oma arsti, apteekri või meditsiiniõega.
English: Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 5000 RÜ/0,5 ml süstelahus süstlis
English: Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 7000 RÜ/0,7 ml süstelahus süstlis
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 2000 RÜ/1 ml süstelahus süstlis
English: Take special care with Abseamed:
Estonian: Eriline ettevaatus on vajalik ravimiga Abseamed
English: Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
Estonian: Iga ml lahust sisaldab 2000 RÜ alfaepoetiini*, mis vastab 16,8 mikrogrammile/ml.
English: Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 1000 RÜ/0,5 ml süstelahus süstlis
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Estonian: Abseamed 10 000 RÜ/1 ml süstelahus süstlis
English: Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Estonian: Iga ml lahust sisaldab 10 000 RÜ alfaepoetiini*, mis vastab 84,0 mikrogrammile/ml.
English: The patients were between 22 months and 72 years old.
Estonian: Patsiendid olid vanuses 22 kuud kuni 72 aastat.
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/ema/.
Estonian: Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu/ema/.
English: Lung damage may occur years after treatment.
Estonian: Kopsukahjustused võivad ilmneda aastaid pärast ravi.
English: It is usually given at least every 6 weeks.
Estonian: Tavaliselt antakse seda vähemalt iga 6 nädala tagant.
English: May cause birth defects.
Estonian: Võib põhjustada sünnidefekte.
English: The duration of the treatment is determined by the doctor and may vary for each patient.
Estonian: Ravi kestuse määrab arst ja see võib iga patsiendi puhul erineda.
English: Other medicines and Carmustine Obvius
Estonian: Muud ravimid ja Carmustine Obvius
English: These may be signs of a severe allergic reaction.
Estonian: Need võivad olla raske allergilise reaktsiooni nähud.
English: Store and transport refrigerated (2°C - 8°C).
Estonian: Hoida ja transportida külmas (2 °C kuni 8 °C).
English: A specialized antidote is not available.
Estonian: Spetsiaalne vastumürk ei ole kättesaadav.
English: Carmustine Obvius may cause the following side effects:
Estonian: Carmustine Obvius võib põhjustada järgmisi kõrvaltoimeid:
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10.
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV 10.
English: Your doctor will talk to you about the possibility of lung damage and allergic reactions and their symptoms.
Estonian: Arst räägib teiega kopsukahjustuste ja allergiliste reaktsioonide võimalikkusest ja nende sümptomitest.
English: Pulmonary toxicity has been observed in up to 30% of patients.
Estonian: Pulmonaalset toksilisust on täheldatud kuni 30%-l patsientidest.
English: Compatibility/Incompatibility with containers
Estonian: Sobimatus/kokkusobimatus mahutitega
English: As a doctor or nurse will be giving you this medicine, it is unlikely that you will receive an incorrect dose.
Estonian: Kuna ravimit annab teile arst või meditsiiniõde, on ebatõenäoline, et saate seda vales annuses.
English: Two of these 8 fatalities occurred within the first 3 years of treatment and 6 of them occurred 8-13 years after treatment.
Estonian: Kaks 8 surmajuhtumist esines esimese 3 raviaasta jooksul ja 6 esines 8...13 aastat pärast ravi.
English: A risk to the newborn/infant cannot be excluded.
Estonian: Riski vastsündinule/imikule ei saa välistada.
English: Therefore this medicine should not normally be administered to pregnant women.
Estonian: Seega tavaliselt ei tohi ravimit manustada rasedatele naistele.
English: Reconstitution and further dilutions should be carried out under aseptic conditions.
Estonian: Manustamiskõlblikuks muutmine ja täiendavad lahjendused tuleb teha aseptilistes tingimustes.
English: What Carmustine Obvius is and what it is used for
Estonian: Mis on Carmustine Obvius ja milleks seda kasutatakse
English: Carmustine Obvius should not be used during pregnancy because it may harm your unborn baby.
Estonian: Carmustine Obviust ei tohi kasutada raseduse ajal, kuna see võib kahjustada sündimata last.
English: This medicine may cause severe (possibly fatal) lung damage.
Estonian: ravim võib põhjustada raskeid (potentsiaalselt surmaga lõppevaid) kopsukahjustusi.
English: The median age of patients who died on treatment was 2.5 years (1-12 years), the median age of long-term survivors on treatment was 10 years (5-16 years).
Estonian: Ravil olles surnud patsientide mediaanvanus oli 2,5 aastat (1...12 aastat); ravil olnud pikaajaliste ellujäänute mediaanvanus oli 10 aastat (5...16 aastat).
English: Doses will be adjusted according to how you respond to the treatment.
Estonian: Annuseid reguleeritakse vastavalt sellele, kuidas ravile reageerite.
English: Carmustine Obvius should not be used in children and adolescents due to high risk of pulmonary toxicity.
Estonian: Carmustine Obviust ei tohi kasutada lastel ja noorukitel pulmonaalse toksilisuse kõrge riski tõttu.
English: Safe use in pregnancy has not been established and therefore the benefit must be carefully weighed against the risk of toxicity.
Estonian: Kasutamise ohutust raseduse ajal ei ole tõendatud ja seega tuleb kasulikkuse vs toksilisuse riski hoolikalt kaaluda.
English: The kinetic of carmustine in humans is characterised by a two-chamber model.
Estonian: Karmustiini kineetikat inimestel iseloomustab kahekambriline mudel.
English: When you are not clear about the fact whether the product is adequately cooled, then you should immediately inspect each and every vial in the carton.
Estonian: Kui te pole kindel, kas ravim on korrektselt säilitatud, peate viivitamatult kontrollima iga viaali karbis.
English: If such symptoms occur, you should contact your doctor immediately (see section
Estonian: Kui selliseid sümptomeid esineb, võtke kohe ühendust arstiga (vt lõik 4).
English: The half-life α is 1-4 minutes and the half-life β is 18-69 minutes.
Estonian: Poolväärtusaeg α on 1...4 minutit ja poolväärtusaeg β on 18...69 minutit.
English: Carmustine Obvius has no or negligible influence on the ability to drive and use machines.
Estonian: Carmustine Obvius ei mõjuta või mõjutab ebaoluliselt autojuhtimise ja masinate käsitsemise võimet.
English: The amount of alcohol in this medicine may alter the effects of other medicines.
Estonian: Ravimis sisalduva alkoholi kogus võib muuta muude ravimite toimet.
English: Because clinical trials are conducted under very specific conditions, the adverse reaction rates observed may not reflect the rates observed in clinical practice.
Estonian: Et kliinilised uuringud tehakse väga spetsiifilistes tingimustes, ei tarvitse ilmnenud kõrvaltoimete määrad kajastada kliinilises praktikas täheldatavaid määrasid.
English: The fate of the remainder is undetermined.
Estonian: Ülejäänu olek on määramata.
English: During treatment, lung function tests (FVC, DLCO) should be performed regularly.
Estonian: Ravi ajal tuleb teha korrapäraselt kopsutalitluse analüüse (FVC, DLCO).
English: Contents of the pack and other information What Carmustine Obvius contains
Estonian: Pakendi sisu ja muu teave Mida Carmustine Obvius sisaldab
English: Approximately 60-70% of a total dose is excreted in the urine in 96 hours and about 10% as respiratory CO2.
Estonian: Ligikaudu 60...70% koguannusest eritub uriinis 96 h jooksul ja umbes 10% respiratoorse CO2na.
English: Tell you doctor or nurse if you have any concern about the amount of medicine that you received.
Estonian: Võtke kohe ühendust arsti või meditsiiniõega, kui tunnete muret seoses ravimi kogusega, mida saate.
English: Long-term follow-up observation of 17 patients who survived brain tumours in childhood showed that 8 of them succumbed to pulmonary fibrosis.
Estonian: Lapsepõlves pärast ajutuumoreid ellujäänud 17 patsiendi pikaajaline järelvaatlus näitas, et neist 8-l tekkis kopsufibroos.
English: There are no limits for the period of application of carmustine therapy.
Estonian: Karmustiinravi rakendamise perioodile piiranguid ei ole.
English: All patients younger than 5 years of age at the time of treatment died from pulmonary fibrosis; neither the carmustine dose nor an additional vincristine dose or spinal radiation had any influence on the fatal outcome.
Estonian: Kõik patsiendid, kes olid ravi ajal alla 5 aasta vanused, surid kopsufibroosi; karmustiiniannus ega täiendav vinkristiiniannus ega seljaaju kiiritusravi ei mõjutanud fataalset lõpptulemust.
English: After the intravenous infusion over 1 hour, the carmustine-plasma level drops in a biphasic manner.
Estonian: Pärast intravenoosset infundeerimist 1 h jooksul langeb karmustiini tase plasmas bifaasiliselt.
English: Carmustine Obvius contains ethanol (alcohol)
Estonian: Carmustine Obvius sisaldab etanooli (alkoholi)
English: Severe (end-stage) renal impairment.
Estonian: Raske (lõppstaadiumi) neerupuudulikkus.
English: Ataxia, dizziness, headache.
Estonian: Ataksia, peapööritus, peavalu.
English: In patients having received carmustine in childhood or adolescence, cases of extremely delayedonset pulmonary fibrosis (up to 17 years after treatment) have been described.
Estonian: Lapsepõlves või noorukieas karmustiini saanud patsientidel on kirjeldatud äärmiselt pika viivitusega ilmnevat kopsufibroosi (kuni 17 aastat pärast ravi).
English: Emetogenic potential.
Estonian: Emetogeenne potentsiaal.
English: 1081 CN Amsterdam The Netherlands
Estonian: 1081 CN Amsterdam Madalmaad
English: Carmustine Obvius will always be given to you by a healthcare professional with experience in the use of anticancer medicines.
Estonian: Carmustine Obviust annab teile alati tervishoiutöötaja, kellel on kogemused vähiravimite kasutamise alal.
English: Melphalan Concomitant use with melphalan leads to increased risk of pulmonary toxicity.
Estonian: Melfalaan Samaaegsel kasutamisel melfalaaniga kaasneb pulmonaalse toksilisuse suurenenud risk.
English: The following schedule is suggested as a guide to dosage adjustment:
Estonian: Järgmine plaan on soovituslik annuse kohandamise juhis:
English: If used during pregancy, the patient must be aware of the potential risk to the unborn baby.
Estonian: Raseduse ajal kasutamisel peab patsient olema teadlik potentsiaalsest ohust sündimata lapsele.
English: This medicine will be stored by your doctor or health care professional.
Estonian: Ravimit säilitab arst või tervishoiutöötaja.
English: This corresponds to 11.2 ml of beer or 4.65 ml wine, per dose.
Estonian: See vastab 11,2 ml õllele või 4,65 ml veinile annuse kohta.
English: Pulmonary toxicity also manifested in the post-marketing phase as pneumonitis and interstitial lung disease.
Estonian: Pulmonaalne toksilisus ilmnes ka turuletuleku järgses faasis pneumoniidi ja interstitsiaalse kopsuhaigusena.
English: The 30 ml stock solution needs to be mixed thoroughly.
Estonian: 30 ml põhilahus tuleb põhjalikult segada.
English: If you use more Carmustine Obvius than you should
Estonian: Kui te kasutate Carmustine Obviust rohkem kui ette nähtud
English: Carmustine Obvius is contraindicated during breastfeeding and up to seven days post-treatment (see section 4.3).
Estonian: Carmustine Obvius on vastunäidustatud imetamise ajal ja kuni seitse päeva pärast ravi (vt lõik 4.3).
English: Carmustine Obvius with alcohol
Estonian: Carmustine Obviuse koos alkoholiga
English: Dosage will also depend on whether Carmustine Obvius is given with other anti-cancer medicines.
Estonian: Annustamine sõltub ka sellest, kas Carmustine Obviust antakse koos teiste vähiravimitega.
English: Dosage is based on your medical condition, body size and response to treatment.
Estonian: Annustamine põhineb teie terviseseisundil, keha suurusel ja ravivastusel.
English: Powder: white to almost white powder or lyophilisate.
Estonian: Pulber: valge kuni peaaegu valge pulber või lüofilisaat.
English: Pharmacotherapeutic group: Antineoplastic agents, alkylating agents, nitrosoureas, ATC code: L01AD01
Estonian: Farmakoterapeutiline rühm: kasvajavastased ained, alküülivad ained, nitrosouuread, ATC-kood: L01AD01
English: The table includes adverse reactions that were presented during treatment with this medicinal product but may not necessarily have a causal relationship with the medicinal product.
Estonian: Tabel sisaldab kõrvaltoimeid, mis ilmnesid ravimpreparaadiga ravimise ajal, kuid millel ei ole ravimpreparaadiga tingimata põhjuslikku seost.
English: However, opinion is divided over the role of the carbamoylating intermediates as mediators of the biological effects of the nitrosoureas.
Estonian: Siiski ollakse eri seisukohtadel karbamoüülivate vaheühendite rolli üle nitrosouureate bioloogiliste toimete vahendajatena.
English: Because of the good lipid solubility and the lack of ionisation at the physiological pH, carmustine is very well transferred through the blood-brain barrier.
Estonian: Hea lipiidlahustuvuse ja ioniseerimise puudumise tõttu füsioloogilise pH juures kandub karmustiin väga hästi läbi hematoentsefaalbarjääri.
English: What you need to know before you use Carmustine Obvius Do not use Carmustine Obvius:
Estonian: Mida on vaja teada enne Carmustine Obviuse kasutamist Ärge kasutage Carmustine Obviust:
English: A repeat course of Carmustine Obvius should not be given until circulating blood elements have returned to acceptable levels (platelets above 100,000/mm3, leukocytes above 4,000/mm3), and this is usually in six weeks.
Estonian: Carmustine Obviuse korduskuuri ei tohi teha, kuni on taastunud ringleva vere elementide aktsepteeritav tase (trombotsüüdid üle 100 000/mm3, leukotsüüdid üle 4000/mm3); tavaliselt toimub see kuue nädala jooksul.
English: To be taken into account in high-risk groups such as patients with liver disease or epilepsy.
Estonian: Sellega tuleb arvestada kõrge riskigrupiga patsientide puhul, nt maksahaigused või epilepsia.
English: Nausea and vomiting are severe and begins within 2-4 h of administration and lasts for 4-6 h.
Estonian: Iiveldus ja oksendamine on tugev ning algab 2...4 h jooksul manustamisest ja kestab 4-6 h.
English: Levels of radioactivity in the cerebrospinal fluid are at least 50% higher than those measured concurrently in plasma.
Estonian: Radioaktiivsuse tase tserebrospinaalvedelikus on plasmas mõõdetavast vähemalt 50% kõrgem.
English: What Carmustine Obvius is and what it is used for What you need to know before Carmustine Obvius is given to you How to use Carmustine Obvius
Estonian: Mis on Carmustine Obvius ja milleks seda kasutatakse Mida on vaja teada enne Carmustine Obviuse kasutamist Kuidas Carmustine Obviust kasutada Võimalikud kõrvaltoimed
English: Pneumonitis.
Estonian: Pneumoniit.